Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
DNA Research
Study data from L. Steinaa et al provide new insights into DNA research
April 16th, 2008
"It is of major importance to overcome the immunological tolerance in attempts to generate efficient tumour vaccines. Here, we describe induction of autoantibodies and self-reactive CTL in three types of OVA-transgenic mouse strains, RIP-OVA(low), RIP-mOVA and RIP-OVA(HI) exhibiting varying levels of OVA expression and tolerance," researchers in Denmark report. "This was achieved by immunizing with DNA constructs where a foreign T-helper epitope, P30 from tetanus toxin, was inserted into the OVA sequence. OVA wild-type DNA as well as the P30-modified OVA DNA vaccines (OVA-P30) were constructed and used for immunization in the OVA-transgenic mouse strains as well as in...
Source: Vaccine Weekly (2008-04-16)
|
